MoneyWorks4Me

Gland Pharma informs about conclusion of US FDA inspection at pashamylaram facility

26 Sep 2023 Evaluate
Further to intimation dated June 27, 2023, Gland Pharma has informed that following the Pre-Approval Inspection (PAI) for Seven (7) products and Good Manufacturing Practice (GMP) Inspection by US FDA at the Company’s Pashamylaram Facility at Hyderabad between 15th June, 2023 and 27th June, 2023, the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1863.00
Dr. Reddys Labs. 1216.20
Cipla 1377.05
Lupin 2118.40
Zydus Lifesciences 1171.00
View more..